Neoimmunetech Inc

Chart & performance

D1W1MN

P/E

—

P/S

0.38

EPS

—

Div yield, %

—

Shrs. gr., 5y

-45.53%

Rev. gr., 5y

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

As a clinical-stage biotechnology firm with a strong focus on T cells, NeoImmuneTech, Inc. is dedicated to creating and marketing innovative immunotherapies. The company's lead product, NT-I7, is a long-acting human IL-7 currently in clinical development for its potential to treat a range of oncologic and infectious conditions. Founded in 2014, NeoImmuneTech is based in Rockville, Maryland.

URL

https://neoimmunetech.com/index.html

IPO date

Mar 16, 2021

Employees

Domiciled in

Incorporated in

Valuation

No data to show